Author: Bret Jensen, Biotech Gems

They’re at the top of my shopping list at the moment…

They appear to have bottomed recently and can look forward to better days in the year ahead…

The company sports gross margins north of 80%, its balance sheet is pristine with no net debt, it invests heavily in R&D, over the next five years it should throw off $50-$70 billion in free cash flow, it initiated its first dividend this year, and it has a $15 billion stock buyback program in place. On top of all of this, earnings are growing and shares sell for less than nine times this year’s profits…

They’re a good place to deploy “dry powder” into on any additional dips in the market…